Previous Page
UK
Deal Maker of the Year Awards 2013 WINNER - HENRY TALBOT-PONSONBY
DEAL: North West Fund for Biomedical invests in TTS Pharma
NAME: Henry Talbot-Ponsonby COMPANY: VCP Advisors POSITION: Managing Partner ADDRESS:
TEL: +44 207 858 1299 DEAL OVERVIEW
VCP was retained by TTS Pharma Limited (TTS) as lead corporate finance adviser with a mandate to advise the company on raising investment funds. TTS is a pioneer in the personalised medicine arena: right drug to the right patient at the right dose. TTS’ proprietary IP allows the pharmacogenetic stratification of patients and thereby accurate prescriptive treatment. By targeting treatment to the patient, TTS is able to increase a treatment’s effectiveness, and thereby reduce the cost of its delivery. This gives TTS’ technology both an emerging and developed market appeal. Having identified the UK and China as the key initial markets for its products, it was essential that TTS built an investor base that was both comfortable with and supportive of the China plans. Working closely with TTS’ management team, VCP successfully raised capital from a number of private investors including the cornerstone investor, Spark Ventures’ North West Fund for BioMedical.
VCP’s success in the TTS transaction ❝ BIO
Henry is Managing Partner at VCP Advisors. He began his career as a Barrister having been called to the Bar by the Inner Temple. Following a move into investment banking, he worked with Grisons Peak, a corporate finance advisory firm focused on European mid-market financial institutions. From there, Henry founded Venture Capital Partners (VCP), a sector generalist advisory and capital raising firm focused on small and medium sized enterprises in Europe. VCP’s success was borne out of its ability to raise capital for its clients from its established network of institutions, family offices and ultra-high net worth individuals. In light of this success, VCP was able to expand its advisory services to private equity funds and hedge funds. To better reflect this more diverse service offering, the company rebranded to VCP Advisors. Headquartered in London, VCP Advisors has an office in Beijing, and is opening an office in New York in Q1 2014.
28 Eccleston Square London SW1V 1NZ
demonstrates its ability to raise capital from both institutional and ‘off the radar’ private investors. Through its close links to, and constant dialogue with, this network of family office and institutional investors, VCP builds a clear picture of the types of companies that investors are seeking. It then analyses the
market place to find the companies that best meet these strict criteria. With significant dry-powder held in investment funds across Europe, VCP sees huge demand for profitable, high growth companies and this is only set to increase as credit conditions continue to improve and the M&A market thaws.
By targeting treatment to the patient, TTS is able to increase a treatment’s effectiveness, and thereby reduce the cost of its delivery.
❝